Study demonstrates adherence to disease-modifying therapies in pregnant MS patients can reduce hospitalization events
ORLANDO — AllianceRx Walgreens Prime recently announced results from research analyzing data of females with multiple sclerosis (MS) who became pregnant, and the impact of adherence to their disease-modifying therapies (DMTs) on hospital utilization and cost. Researchers wanted to understand how non-adherence to their DMTs would impact healthcare cost and utilization over a two-year period. The findings suggest
